BLUE bluebird bio Inc.

82.95
-1  -1%
Previous Close 83.96
Open 84.14
Price To Book 3.12
Market Cap 4,589,983,105
Shares 55,331,000
Volume 476,570
Short Ratio
Av. Daily Volume 1,372,903
Stock charts supplied by TradingView

NewsSee all news

  1. bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

    First agreements with statutory health insurances utilize bluebird's innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center

  2. bluebird bio Announces Investor Events in January

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January: Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A

  3. bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

    Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 bluebird bio, Inc. (NASDAQ:BLUE) and

  4. bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin™ Gene Therapy for β-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition

    More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a

  5. bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

    99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 1H 2020.
LentiGlobin - HGB-210
Sickle Cell Disease (SCD)
Phase 3 updated data 2H 2020.
LentiGlobin - HGB-212 Northstar-3
TDT and the β0/β0genotype
BLA filing due 1H 2020.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 3 updated data 2H 2020.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
BLA filing 2H 2020.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data at ASH December 2019 - median weighted average Hb during TI of 10.3 g/dL.
LentiGlobin - HGB-204
β-Thalassemia
Phase 1/2 updated data 2H 2020.
LentiGlobin - HGB-206
Sickle disease
Phase 1 data at ASH December 9, 2019 - 83% complete response.
bb21217
Multiple Myeloma

Latest News

  1. bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

    First agreements with statutory health insurances utilize bluebird's innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center

  2. bluebird bio Announces Investor Events in January

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January: Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A

  3. bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

    Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 bluebird bio, Inc. (NASDAQ:BLUE) and

  4. bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin™ Gene Therapy for β-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition

    More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a

  5. bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

    99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at

  6. Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

    Study met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population Safety results are consistent with the data presented

  7. bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology Annual Meeting

  8. bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

    bluebird bio, Inc. (NASDAQ:BLUE) and Forty Seven, Inc. (NASDAQ:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based

  9. bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

    Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for

  10. bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

    - Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined

  11. bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020. "On behalf of bluebird, we are grateful for

  12. European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™

    First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype now available to be manufactured in the European Union bluebird bio, Inc. (NASDAQ:BLUE)

  13. bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

    bluebird bio, Inc. (NASDAQ:BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases,

  14. bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that it has appointed William R. Sellers, M.D. to its Board of Directors. "I'm excited to welcome Bill to the Board to help navigate an important stage in bluebird's

  15. bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of

  16. bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD bluebird bio, Inc. (NASDAQ:BLUE)

  17. bluebird bio Announces Investor Events in September

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14th Annual Biotech Conference, Wednesday, September